Analysis of Turkish Pharmaceutical Sector PDF Download

Author: Mehmet ATASEVER
Publisher: Matasever
ISBN:
Category : Business & Economics
Languages : en
Pages : 158

View

Book Description
"Analysis of Turkish Pharmaceutical Sector" is a comprehensive book that analyzes Turkish pharmaceutical industry, its financial structure and developments affecting industry from different perspectives. The book examines how pharmaceutical sector developed in Turkey after the policies followed since 2003, financing of the sector, pharmaceutical expenditures via detailed analyses and investigates the current situation, strategies and objectives of the sector. Pharmaceutical expenditures projected in the book covers expenditure statistics of 2002 -2013 period prepared by Turkey Statistical Institute (TurkStat).

Author: IBP, Inc.
Publisher: Lulu.com
ISBN: 1438748965
Category : Business & Economics
Languages : en
Pages : 264

View

Book Description
2011 Updated Reprint. Updated Annually. Turkey Medical & Pharmaceutical Industry Handbook

Author: Raymond A. Huml
Publisher: Springer Nature
ISBN: 3030786056
Category : Medical
Languages : en
Pages : 418

View

Book Description
This book provides a broad overview of rare disease drug development. It offers unique insights from various perspectives, including third-party capital providers, caregivers, patient advocacy groups, drug development professionals, marketing and commercial experts, and patients. A unique reference, the book begins with narratives on the many challenges faced by rare disease patient and their caregivers. Subsequent chapters underscore the critical, multidimensional role of patient advocacy groups and the novel approaches to related clinical trials, investment decisions, and the optimization of rare disease registries. The book addresses various rare disease drug development processes by disciplines such as oncology, hematology, pediatrics, and gene therapy. Chapters then address the operational aspects of drug development, including approval processes, development accelerations, and market access strategies. The book concludes with reflections on the authors' case for real-world data and evidence generation in orphan medicinal drug development. Rare Disease Drug Development is an expertly written text optimized for biopharmaceutical R&D experts, commercial experts, third-party capital providers, patient advocacy groups, patients, and caregivers.

Author: OECD
Publisher: OECD Publishing
ISBN: 9264051090
Category :
Languages : en
Pages : 141

View

Book Description
This comprehensive review of Turkey's health care system shows how Turkey recently brought universal health care to its population and assesses the challenges that remain.

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309269393
Category : Medical
Languages : en
Pages : 377

View

Book Description
The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines.

Author: Alpaslan Özerdem
Publisher: Routledge
ISBN: 1351387472
Category : Social Science
Languages : en
Pages : 529

View

Book Description
The Routledge Handbook of Turkish Politics pulls together contributions from many of the world’s leading scholars on different aspects of Turkey. Turkey today is going through possibly the most turbulent period in its history, with major consequences both nationally and internationally. The country looks dramatically different from the Republic founded by Atatürk in 1923. The pace of change has been rapid and fundamental, with core interlinked changes in ruling institutions, political culture, political economy, and society. Divided into six main parts, this Handbook provides a single-source overview of Turkish politics: Part I: History and the making of Contemporary Turkey Part II: Politics and Institutions Part III: The Economy, Environment and Development Part IV: The Kurdish Insurgency and Security Part V: State, Society and Rights Part VI: External Relations This comprehensive Handbook is an essential resource for students of Politics, International Relations, International/Security Studies with an interest on contemporary Turkey.

Author: Zaheer-Ud-Din Babar
Publisher: Springer
ISBN: 3319121693
Category : Business & Economics
Languages : en
Pages : 410

View

Book Description
This book provides an overview of the global pharmaceutical pricing policies. Medicines use is increasing globally with the increase in resistant microbes, emergence of new treatments, and because of awareness among consumers. This has resulted in increased drug expenditures globally. As the pharmaceutical market is expanding, a variety of pharmaceutical pricing strategies and policies have been employed by drug companies, state organizations and pharmaceutical pricing authorities.

Author: Songül Çınaroğlu
Publisher: Routledge
ISBN: 100021463X
Category : Business & Economics
Languages : en
Pages : 154

View

Book Description
Ensuring equity in healthcare is the main concern of health policymakers in order to provide a sustainable health system. This concern is more prominent in developing countries due to the scarcity of resources. This book provides a comprehensive analysis and discussion on the distributive pattern of out-of-pocket pharmaceutical expenditures under the health reforms in Turkey and makes comparisons with pharmerging countries. Turkey’s health reforms began in 2003 to address shortcomings related to financial protection and to improve health outcomes and the quality of healthcare services. The primary motivation was to ensure equity in the distribution of health resources, and this transformation process led to profound changes in how these resources were used, and in health financing in general. However, there is a lack of knowledge regarding the long-term effect of health reforms on the distribution patterns of health expenditures and health service use. This book offers a thorough equity analysis of the health financing system, affected by this health transformation program. Index and curve approaches are used in the equity analysis of pharmaceutical expenditures. The book examines the long-term effects of health system regulations on the health spending characteristics of households and improves the current understanding of equity in this context. It includes extensive international comparisons of healthcare services across a range of developing countries and highlights the significance of ensuring equity for emerging economies. The author explores the existing evidence as well as future research directions and provides policy and planning advice for health policymakers to contribute to establishing a more equal health system design. Additionally, the book will be of interest to scholars and professionals in the fields of health economics, public health management and health financing.

Author: Menghis Bairu
Publisher: Academic Press
ISBN: 0124158609
Category : Medical
Languages : en
Pages : 332

View

Book Description
Pharmaceuticals companies, biotech companies, and CROs, regardless of size, all face the same challenge of managing costs and operational execution associated with bringing a valuable drugs and devices to market. Because of timeline pressures and cost as well as the growing interest in "neglected diseases" and diseases affecting the emerging nations, clinical trials are increasingly conducted in emerging markets and developing countries where infrastructure, leadership, skilled personnel and a governance are at a premium. Working with academics, regulatory professionals, safety officers, experts from the pharma industry and CROs, the editors have put together this up-to-date, step-by-step guide book to building and enhancing global clinical trial capacity in emerging markets and developing countries. This book covers the design, conduct, and tools to build and/or enhance human capacity to execute such trials, appealing to individuals in health ministries, pharmaceutical companies, world health organizations, academia, industry, and non-governmental organizations (NGOs) who are managing global clinical trials. - Gives medical professionals the business tools needed to effectively execute clinical trials throughout the world - Provides real world international examples which illustrate the practical translation of principles - Includes forms, templates, and additional references for standardization in a number of global scenarios

Author: Hans Löfgren
Publisher: Springer
ISBN: 1137315857
Category : Political Science
Languages : en
Pages : 247

View

Book Description
Some two decades will shortly have passed since the WTO's Trade Related Aspects of Intellectual Property Rights agreement came into force in 1995. This volume is the first cross-country analysis of how TRIPS has affected the capacity of 11 major low or medium income countries to produce generic drugs.